PRESS RELEASE published on 04/05/2024 at 10:10, 2 years 1 month ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 2 years 1 month ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 2 years 1 month ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 2 years 1 month ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
PRESS RELEASE published on 02/09/2024 at 10:52, 2 years 3 months ago Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen APONTIS PHARMA AG hat ein Strategie-Update gegeben und finanzielle Details aus der Restrukturierung bekannt gegeben, was zu einer Reduktion der Break Even-Schwelle führt APONTIS PHARMA AG Strategie-Update Restrukturierung Finanzielle Details Break Even-Schwelle
PRESS RELEASE published on 02/06/2024 at 07:30, 2 years 3 months ago APONTIS PHARMA successfully completes performance and efficiency improvement program APONTIS PHARMA successfully completes performance and efficiency improvement program, reducing headcount and expenses. New go-to-market approach for Single Pill combinations to start on 1 March 2024 Pharmaceutical Company Efficiency APONTIS PHARMA Performance Improvement Single Pill Combinations
PRESS RELEASE published on 11/09/2023 at 07:30, 2 years 6 months ago APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
PRESS RELEASE published on 11/08/2023 at 20:00, 2 years 6 months ago EQS-Adhoc: APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
PRESS RELEASE published on 10/07/2023 at 00:54, 2 years 7 months ago EV Nickel Issues Shares to Rogue and, Rogue Update
PRESS RELEASE published on 10/04/2023 at 13:30, 2 years 7 months ago EVNi Clean Nickel(TM) R&D - Carbon Capture Results Beat Expectations, Great Potential for Carbon Mineralization and Storage – Advancing to Pilot Plant Testing
Published on 05/09/2026 at 01:30, 1 day 2 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 3 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/09/2026 at 19:05, 8 hours 26 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 6 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 8 hours ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 8 hours ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days 8 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 8 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 8 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 8 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 8 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
